The research behind our formulas

follicare is built on Caronositol Fertility®, a patented combination of myo-inositol and D-chiro-inositol in a 3.6:1 ratio, studied in women with PMOS (formerly PCOS). Feminoria uses four Lactobacillus strains studied for vaginal microbiota balance. Each study below links to the published paper.

Which study used the follicare ratio?

Inositol ratio and pregnancy outcomes in women undergoing ICSI (2019)

What was studied: 60 women with PCOS undergoing ICSI (a form of IVF) took either 1,100 mg myo-inositol and 300 mg D-chiro-inositol a day (the 3.6:1 ratio used in follicare) or a standard 40:1 formula, for 12 weeks.
What it found: A pregnancy rate of 65.5% vs 25.9%, and a live-birth rate of 55.2% vs 14.8%, in favour of the 3.6:1 ratio.
Source: Mendoza N, et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019. doi:10.1080/09513590.2019.1576620

What else has been published on inositol?

Studies of myo-inositol and D-chiro-inositol in women with PCOS. Each title links to the paper.

Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach
University of Insubria and University of Verona, Italy
High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial
University of Granada, Clinica MARGEN and Biosearch Life, Spain
Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS
University of Messina, Italy
Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients
University of Modena and Reggio Emilia, Italy
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Institut des Etudes Universitaires, Switzerland; University of Modena and Reggio Emilia, Italy; Virginia Commonwealth University, USA
The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone
Sapienza University of Rome, Italy
Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)
University of Pisa, Italy
The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients
University of Rome, Italy

Which study used Feminoria's strains?

Lactobacillus strains and vaginal microbiota balance (2023)

What was studied: 36 women without symptoms took an oral combination of three of Feminoria's four Lactobacillus strains (CBT-LA1, CBT-LR5, CBT-LU4) for six weeks. Vaginal samples were checked with Nugent scoring, 16S sequencing and qPCR.
What it found: Of the 10 women who started with an imbalanced vaginal-flora score (high Nugent score), 6 moved to a healthy score within six weeks, and vaginal Lactobacillus increased.
Source: Ansari et al. Lactobacillus probiotics improve vaginal dysbiosis in asymptomatic women. Nutrients. 2023;15(8):1862. doi:10.3390/nu15081862

Study titles use "PCOS", the name at the time of publication. Findings describe the groups studied; individual results vary. follicare and Feminoria are food supplements, not medicines.